Gamitrinib TPP

• UNSPSC Description:

  Gamitrinib TPP is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity.

• Target Antigen:

  HSP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Gamitrinib_TPP.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C=C1NC(/C(C)=C/C=C/[C@H](OC)[C@@H](OC(N)=O)/C(C)=C/[C@H](C)[C@H]2O)=O)C(NCCCCCC[P+](C3=CC=CC=C3)(C4=CC=CC=C4)C5=CC=CC=C5)=C(C[C@H](C[C@@H]2OC)C)C1=O

• Molecular Weight:

  891.06

• References & Citations:

  [1]Markus D. Siegelin, et al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 2011 Apr 1; 121(4): 1349–1360.Exp Ther Med. September 2, 2021.|bioRxiv. 2024 Jan 2.|bioRxiv. 2024 September 03.|Cancer Lett. 2022 Sep 13;215915.|Clin Cancer Res. 2022 Mar 4;clincanres.0833.2021.|Elife. 2021 Jun 16;10:e63104.|Front Biosci (Landmark Ed). 2023 Sep 26, 28(9), 227.|Nature. 2020 Mar;579(7799):433-437. |Research Square Preprint. 2020 Sep.|SSRN. 2023 Jul 11.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1131626-46-4